Form 4: DiaMedica Director Acquires Shares via RSU Settlement

DiaMedica Therapeutics Inc. Director Charles Pauling Semba acquired 3,355 shares of common stock through the settlement of restricted stock units, increasing his beneficial ownership to 47,963 shares.

Summary

• Director Charles Pauling Semba acquired 3,355 shares of DiaMedica Therapeutics Inc. common stock.
• The acquisition occurred on January 2, 2026, at a price of $8.42 per share.
• These shares were issued upon the settlement of restricted stock units (RSUs) granted under the company's Amended and Restated 2019 Omnibus Incentive Plan.
• The RSUs were granted in lieu of cash retainer fees totaling $28,250.
• Following this transaction, Mr. Semba beneficially owns 47,963 shares.
• The restricted stock units are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026.

Sentiment

Score: 6

Explanation: A director's acquisition of shares, even through RSU settlement, generally signals confidence in the company's future. It's a routine compensation event, so the sentiment is moderately positive due to insider alignment, but not indicative of extraordinary news.

Positives

• A director increasing their beneficial ownership, even through RSU settlement, can be seen as a positive signal of alignment with shareholder interests.
• The company is utilizing its 2019 Omnibus Incentive Plan to compensate directors, which is a standard practice for aligning management and director incentives with company performance.

Future Outlook

The restricted stock units are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026, indicating future equity compensation events.

Industry Context

This transaction represents a routine equity compensation event for a director, common across publicly traded companies to align executive and director incentives with long-term shareholder value. It does not provide specific insights into broader industry trends but reflects standard corporate governance practices.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of director compensation is a common practice among U.S. public companies, aligning director interests with long-term stock performance.
• The vesting schedule over a year is typical for equity awards, designed to retain directors and incentivize sustained performance.
• The value of the RSU grant ($28,250) in lieu of cash retainer fees is within the typical range for non-executive director compensation at small to mid-cap biotechnology companies, though specific comparisons would require detailed peer group analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders through equity ownership.

Next Steps

• The restricted stock units will vest in four equal installments on March 31, June 30, September 30, and December 31, 2026.

Key Dates

Keywords

DiaMedica Therapeutics, DMAC, Form 4, Insider Trading, Restricted Stock Units, RSU, Director Compensation, Equity Compensation, Beneficial Ownership